Therapeutic antibodies against immune checkpoint receptors, such as PD-1 and CTLA-4, along with adoptive transfer of genetically engineered chimeric antigen-receptor (CAR)-T cells, have demonstrated tremendous success in treating some cancers. Here, PDCD1 is linked to cancer.